Immune adjuvant – Japan (Patent No. 5242855)

Patent Details

Aureobasidium (black yeast) culture medium (hereafter referred to as “Aureo culture medium”) was tested as an “adjuvant” substance to further enhance the efficacy of the intranasal vaccine.

The group that received the intranasal vaccine alone showed higher antibody titers for both IgA and IgG than the group that received the intranasal vaccine in combination with the Aureo culture medium.

These results indicate that Aureo culture medium has an adjuvant effect for intranasal vaccines.

Adjuvant: A substance that aids or enhances the effect of a vaccine.
IgA: Antibody that exists in large quantities in mucous membranes
IgG: Antibody that exists in large quantities in the serum

関連するおすすめコンテンツ

Therapeutic agent for influenza virus infection – Japan (Patent No. 5560472) Therapeutic agent for influenza virus infection-EU (European Patent No. 2486931) Therapeutic agent for influenza virus infection-EU (European Patent No. 2486931) Therapeutic agent for influenza virus infection – Taiwan (Taiwan Patent Invention No. I496578)